Jacobio Pharmaceuticals Group Future Growth

Future criteria checks 0/6

Jacobio Pharmaceuticals Group is forecast to grow revenue at 59.2% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	35.3%
Revenue growth rate	59.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	02 Apr 2024

Recent future growth updates

Recent updates

We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

May 10

Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

Aug 26

We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

Jul 29

We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

Apr 29

What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Mar 21

Earnings and Revenue Growth Forecasts

SEHK:1167 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	207	N/A	N/A	N/A	1
12/31/2025	60	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
12/31/2023	64	-359	N/A	N/A	N/A
9/30/2023	72	-385	N/A	N/A	N/A
6/30/2023	81	-410	-449	-400	N/A
3/31/2023	89	-391	-379	-346	N/A
12/31/2022	96	-372	-309	-292	N/A
9/30/2022	123	-332	-230	-218	N/A
6/30/2022	150	-292	-151	-145	N/A
3/31/2022	151	-297	-155	-146	N/A
12/31/2021	153	-301	-159	-147	N/A
9/30/2021	348	-570	-70	-56	N/A
6/30/2021	544	-839	18	36	N/A
3/31/2021	515	-1,177	43	57	N/A
12/31/2020	486	-1,514	68	79	N/A
9/30/2020	243	-1,298	-37	-30	N/A
6/30/2020	N/A	-1,082	-141	-139	N/A
3/31/2020	N/A	-753	-129	-126	N/A
12/31/2019	N/A	-425	-116	-113	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1167's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if 1167's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 1167's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1167 is forecast to have no revenue next year.

High Growth Revenue: 1167 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1167's Return on Equity is forecast to be high in 3 years time

Jacobio Pharmaceuticals Group Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 86%

Consensus revenue estimates fall by 12%

Recent updates

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Full year 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.49 loss in FY 2022)

Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 07, 2024

Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI

Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium

Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo

Executive Chairman & CEO recently bought HK$594k worth of stock

First half 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.17 loss in 1H 2022)

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Jacobio Pharmaceuticals Group Co., Ltd.'S In-House KRAS G12C Inhibitor Jab-21822 (Glecirasib) Granted Breakthrough Therapy Designation for Pancreatic Cancer Patients

Jacobio Pharmaceuticals Group Co., Ltd. announced that it expects to receive CNY 150 million in funding from Beijing E-Town International Investment & Development Co., Ltd.

Consensus revenue estimates fall by 86%

Jacobio Pharmaceuticals Group Co., Ltd. Presents Clinical Results of Glecirasib in Colorectal Cancer

Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval for PARP7 Inhibitor JAB-26766 in China

We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

Full year 2022 earnings released: CN¥0.49 loss per share (vs CN¥0.40 loss in FY 2021)

Jacobio Pharma Completes First Patient Dosage of Aurora Inhibitor JAB-2485 in U.S

Jacobio's Kras G12c Inhibitor JAB-21822 Was Granted Breakthrough Therapy Designations by China Cde

Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022

Less than half of directors are independent

Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China

Jacobio Pharma Completes First Patient Dosage of Cd73 Mab Jab-Bx102 in China

Jacobio Pharmaceuticals Group Co., Ltd. Announces First Patient Dosed with JAB-21822 in the Phase IIa Trial on KRAS G12C and STK11 Co-Mutation

Consensus revenue estimates fall by 12%

Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

Jacobio Pharmaceuticals Group Co., Ltd. Announces Change of Joint Company Secretary

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2022 Results on Aug 23, 2022

We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

Jacobio Pharma will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting

We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

Less than half of directors are independent

Board Member recently bought HK$91k worth of stock

Senior VP & Executive Director recently bought HK$150k worth of stock

Senior VP & Executive Director recently bought HK$336k worth of stock

Jacobio Pharmaceuticals Group Co., Ltd. JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China

Senior VP & Executive Director recently bought HK$1.6m worth of stock

Jacobio Pharmaceuticals Group Co., Ltd. Announces Investigational New Drug Approval of Aurora A Inhibitor JAB-2485 from Food and Drug Administration of the United States

Jacobio Pharma Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of Kras G12c Inhibitor for Solid Tumor

Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering $20 Million Milestone Payment

Jacobio Announces FDA Approves IND Application to Develop KRAS G12c Inhibitor

Joint Company Secretary has left the company

What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Jacobio Pharmaceuticals Group Co., Ltd. Together with Its Subsidiaries Receive Two Investigational New Drug (The "IND") Approvals to Initiate Clinical Trials for Its Shp2 Inhibitors

Jacobio Pharmaceuticals Group Co., Ltd. has completed an IPO in the amount of HKD 1.350665 billion.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies